1-4 of 4
Marek Kania
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

Anu Doraiswamy, Vijayvel Jayaprakash, Marek Kania, Marjo Hahka-Kemppinen, Zhao Yang, Mark Rudinski, Farhad Ravandi
Journal: Blood
Blood (2021) 138 (Supplement 1): 4438.
https://doi.org/10.1182/blood-2021-145636
Published: 2021
Journal Articles

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Paolo Strati, Dominik Chraniuk, Eva González-Barca, Michal Taszner, Rathi Pillai, Caly Chien, Shivani Nanda, Mark Rudinski, Vijayvel Jayaprakash, Marjo Hahka-Kemppinen, Marek Kania
Journal: Blood
Blood (2021) 138 (Supplement 1): 2432.
https://doi.org/10.1182/blood-2021-145641
Published: 2021
Journal Articles

A Phase 1 Study of HMPL-523, Highly Selective and Potent a Small Molecule Inhibitor of Spleen Tyrosine Kinase in Patients with Relapsed or Refractory Lymphoma

Tunde Lawrence, MD PhD, Marjo Hahka-Kemppinen, MD, Paolo Strati, MD, Marek Kania, MD MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 17.
https://doi.org/10.1182/blood-2020-141451
Published: 2020
Journal Articles

A Phase 1 Study of HMPL-689, a Small Molecule, Highly Selective, and Potent Inhibitor of Phosphoinositide 3 Kinase-Delta, in Patients with Relapsed or Refractory Lymphoma

Tunde Lawrence, MD PhD, Marjo Hahka-Kemppinen, MD, Jonathon B. Cohen, MDMS, Marek Kania, MD MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-141465
Published: 2020